Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study
Pituitary
.
2015 Jun;18(3):395-6.
doi: 10.1007/s11102-014-0628-z.
Authors
Michael Sheppard
1
,
Marcello D Bronstein
,
Pamela Freda
,
Omar Serri
,
Laura De Marinis
,
Luciana Naves
,
Liudmila Rozhinskaya
,
Karina Hermosillo Reséndiz
,
Matthieu Ruffin
,
YinMiao Chen
,
Annamaria Colao
Affiliation
1
Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK, m.c.sheppard@bham.ac.uk.
PMID:
25566750
PMCID:
PMC4643589
DOI:
10.1007/s11102-014-0628-z
No abstract available
Publication types
Published Erratum